

□ No

□ No

□ Yes

□ Yes





https://providers.amerigroup.com

Siliq (brodalumab) Prior Authorization of Benefits Form

CONTAINS CONFIDENTIAL PATIENT INFORMATION

Complete form in its entirety and fax to: Prior Authorization of Benefits Center at 1-844-512-9004 Provider Help Desk 1-800-454-3730

1. Patient information		2. Physician information		
Patient name:		Prescribing physician:		
Patient ID #:		Physician address:		
Patient DOB:		Physician phone #:		
Date of Rx:		Physician fax #:		
Patient phone #:		Physician specialty:		
Patient email address:		Physician DEA:		
		Physician NPI #:		
		Physician email address:		
3. Medication	4. Strength	5. Directions	6. Quantity per 30 days	
			Specify:	
Siliq (brodalumab)				
7. Diagnosis:				
8. Approval criteria: (Check all boxes that apply. Note: Any areas not filled out are considered not applicable to your patient and may affect the outcome of this request.)				
Required for All Requests:				
□ Yes □ No Patient h			E: patients with active hepatitis B will	
			Hepatitis B infection (Hepatitis ney are received	
effective a	antiviral treatment			
			skin cancer, or lymphoproliferative ent with a biological agent [PLEASE	
NOTE: B	Biological agents include: Aba	atacept (Orencia); Adalimur	mab (Humira); Anakinra (Kineret);	
	ımab Pegol (Cimzia); Etanero nab (Actemra); Ustekinumab		emicade); Golimumab (Simponi); Cosentyx)]	

IAPEC-1186-18 October 2018

class III or IV and with an ejection fraction of 50% or less

Patient has a diagnosis of congestive heart failure (CHF) that is New York Heart Association (NYHA)

Patient has been screened for latent TB infection [PLEASE NOTE: patients with latent TB will only be

□ Yes	□ No	considered after one month of TB treatment and patients with active TB will only be considered upon completion of TB Treatment] The request medication will be given concurrently with live vaccines.		
Plaque Psoriasis:				
□ Yes	□ No	Patient has a diagnosis of plaque psoriasis		
□ Yes	□ No	Patient had an inadequate response to phototherapy, systemic retinoids (oral isotretinoin), methotrexate, or cyclosporine or there is clinical evidence that the use of these agents would be medically contraindicated. *DOCUMENTATION must be submitted which includes the following information: the patient had an inadequate response to phototherapy, systemic retinoids (oral isotretinoin), methotrexate, or cyclosporine or there is clinical evidence that the use of these agents would be medically contraindicated Documentation may include, but is not limited to, chart notes, prescription claims records, prescription receipts, and laboratory data.		
□ Yes	□ No	Patient had a previous trial and therapeutic failure with TWO preferred biological medications or there is clinical evidence that the use of these agents would be medically contraindicated. [Please Note the PREFERRED biologic medications are: Cosentyx, Enbrel, and Humira.] *DOCUMENTATION must be submitted which includes the following information: the patient has had previous trials and therapy failures with two preferred biological agents or there is clinical evidence that the use of these agents would be medically contraindicated. Documentation may include, but is not limited to, chart notes, prescription claims records, prescription receipts, and laboratory data.		
9. Physician signature				

Prior Authorization of Benefits is not the practice of medicine or the substitute for the independent medical judgment of a treating physician. Only a treating physician can determine what medications are appropriate for a patient. Please refer to the applicable plan for the detailed information regarding benefits, conditions, limitations and exclusions. The submitting provider certifies that the information provided is true, accurate and complete and the requested services are medically indicated and necessary to the health of the patient.

Note: Payment is subject to member eligibility. Authorization does not guarantee payment.

The document(s) accompanying this transmission may contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents.

Important note: You are not permitted to use or disclose Protected Health Information about individuals who you are not treating or are not enrolled to your practice. This applies to Protected Health Information accessible in any online tool, sent in any medium including mail, email, fax or other electronic transmission.